Erlotinib — mesenchymal druggability
Inhibition of Erlotinib across the 47 mesenchymal-specific kinases of Table S9 (1 µM single dose). Weighted inhibition 11.6% · mean inhibition 11.5% · 2/47 kinases inhibited to ≤ 35% residual activity.
Strongest inhibition shown left. Inhibition % = 100 − residual activity %.
Per-kinase profile
| Kinase (RBC label) | HGNC | Residual % | Inhibition % | Mes/epi fold-change | Status |
|---|---|---|---|---|---|
| EGFR | EGFR | 0.6 | 99.4 | 1.50 | Upregulated |
| ABL2_ARG | ABL2 | 33.2 | 66.8 | 1.66 | Upregulated |
| DDR2 | DDR2 | 48.8 | 51.2 | 3.68 | Upregulated |
| PEAK1 | PEAK1 | 55.6 | 44.4 | 1.59 | Upregulated |
| C_MET | MET | 65.6 | 34.4 | 1.20 | Upregulated |
| FGFR1 | FGFR1 | 79.3 | 20.7 | 2.73 | Upregulated |
| DYRK3 | DYRK3 | 82.6 | 17.4 | 1.57 | Upregulated |
| ALK2_ACVR1 | ACVR1 | 84.3 | 15.7 | 1.66 | Upregulated |
| FYN | FYN | 86.0 | 14.0 | 1.85 | Upregulated |
| PDGFRA | PDGFRA | 86.3 | 13.7 | 2.74 | Upregulated |
| ARK5_NUAK1 | NUAK1 | 86.9 | 13.1 | 1.97 | Upregulated |
| LIMK1 | LIMK1 | 87.1 | 12.9 | 1.10 | Upregulated |
| EPHA5 | EPHA5 | 87.5 | 12.5 | 1.50 | Upregulated |
| PKCMU_PRKD1 | PRKD1 | 88.6 | 11.4 | 2.02 | Upregulated |
| EPHA2 | EPHA2 | 89.2 | 10.8 | 1.22 | Upregulated |
| JAK1 | JAK1 | 89.4 | 10.6 | 1.17 | Upregulated |
| PDGFRB | PDGFRB | 91.8 | 8.2 | 3.93 | Upregulated |
| PKCNU_PRKD3 | PRKD3 | 92.0 | 8.0 | 1.04 | Upregulated |
| PKACB | PRKACB | 92.3 | 7.7 | 1.25 | Upregulated |
| CAMK2D | CAMK2D | 92.4 | 7.6 | 1.19 | Upregulated |
| DRAK1_STK17A | STK17A | 92.6 | 7.4 | 1.98 | Upregulated |
| DLK_MAP3K12 | MAP3K12 | 93.0 | 7.0 | 1.29 | Upregulated |
| BMPR2 | BMPR2 | 93.1 | 6.9 | 1.10 | Upregulated |
| STK32B_YANK2 | STK32B | 94.6 | 5.4 | 1.72 | Upregulated |
| PLK2 | PLK2 | 95.0 | 5.0 | 2.42 | Upregulated |
| SGK1 | SGK1 | 95.3 | 4.7 | 2.88 | Upregulated |
| MLCK_MYLK | MYLK | 96.0 | 4.0 | 4.25 | Upregulated |
| EPHB2 | EPHB2 | 96.2 | 3.8 | 1.15 | Upregulated |
| EPHA4 | EPHA4 | 96.5 | 3.5 | 1.10 | Upregulated |
| DCAMKL2 | DCLK2 | 96.7 | 3.3 | 1.52 | Upregulated |
| CAMK4 | CAMK4 | 97.2 | 2.8 | 1.06 | Upregulated |
| TIE2_TEK | TEK | 97.5 | 2.5 | 1.16 | Upregulated |
| HIPK2 | HIPK2 | 99.0 | 1.0 | 1.12 | Upregulated |
| NEK7 | NEK7 | 99.2 | 0.8 | 1.54 | Upregulated |
| NEK6 | NEK6 | 99.2 | 0.8 | 1.67 | Upregulated |
| RSK3 | RPS6KA2 | 99.6 | 0.4 | 1.66 | Upregulated |
| AKT3 | AKT3 | 99.9 | 0.1 | 2.59 | Upregulated |
| CAMK1A | CAMK1 | 100.0 | 0.0 | 1.86 | Upregulated |
| AXL | AXL | 100.0 | 0.0 | 5.65 | Upregulated |
| TGFBR2 | TGFBR2 | 100.0 | 0.0 | 2.39 | Upregulated |
| ZIPK_DAPK3 | DAPK3 | 100.0 | 0.0 | 1.16 | Upregulated |
| MEKK3 | MAP3K3 | 100.0 | 0.0 | 1.03 | Upregulated |
| CDK15_CYCLIN_A2 | CDK15 | 100.0 | 0.0 | 2.05 | Upregulated |
| ALK5_TGFBR1 | TGFBR1 | 100.0 | 0.0 | 1.12 | Upregulated |
| LATS2 | LATS2 | 100.0 | 0.0 | 1.37 | Upregulated |
| HGK_MAP4K4 | MAP4K4 | 100.0 | 0.0 | 1.66 | Upregulated |
| PKCA | PRKCA | 100.0 | 0.0 | 2.09 | Upregulated |